Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients

Published:2015-02-02 Issue:4 Volume:45 Page:336-342
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:Japanese Journal of Clinical Oncology

Author:

Feng Y.-M.,Feng C.-W.,Lu C.-L.,Lee M.-Y.,Chen C.-Y.,Chen S. C.-C.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/45/4/336/2698643/hyv007.pdf

Reference23 articles.

1. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis

2. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

3. Management of hepatocellular carcinoma: An update

4. Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects

5. Sorafenib in Advanced Hepatocellular Carcinoma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment with Antihistamines and the Risk of Liver Cancer in Patients with Viral Hepatitis: A Multi-Center Cohort Study;Viruses;2024-06-11

2. The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis;Frontiers in Oncology;2023-09-25

3. Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma;World Journal of Gastroenterology;2023-05-07

4. Association of Antihistamine Use with Increased Risk of Esophageal Squamous Cell Carcinoma: A Nationwide, Long-Term Follow-Up Study Using Propensity Score Matching;Biomedicines;2023-02-16

5. H1-Antihistamine Use Is Associated With Increased Esophageal Squamous Cell Carcinoma Risk (Preprint);2023-01-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3